# Voyager to Present at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/VYGR/voyager-to-present-at-upcoming-investor-conferences-a9ba72db
Ticker: VYGR
Company: Voyager Therapeutics
Source: Voyager Therapeutics
Published: 2026-02-09 13:00 EST
## Summary

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics...

## Article Body
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026 : Fireside chat at 1:00 p.m. ET on Wednesday, February 11, 2026, in New York, NY.

Oppenheimer 36th Annual Healthcare Life Sciences Conference: Fireside chat at 3:20 p.m. ET on Thursday, February 26, 2026.

TD Cowen 46th Annual Health Care Conference: Fireside chat at 1:10 p.m. ET on Monday, March 2, 2026, in Boston, MA.

Leerink Global Healthcare Conference 2026: Fireside chat at 10:40 a.m. ET on Tuesday, March 10, 2026, in Miami, FL.

Stifel 2026 CNS Days: Fireside chat on Wednesday, March 18, 2026.

A webcast of the Oppenheimer fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com . A replay of the webcast will be archived on the company’s website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts

Trista Morrison, NACD.DC, tmorrison@vygr.com Investors: Sarah McCabe, smccabe@jpa.com Media: Adam Silverstein, adam@scientpr.com
## Recent Company News
- 2026-07-13 12:01 EST — [Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026](https://biopharmsignal.com/news/VYGR/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-in-6-mo-d6b19d18) — Source: Voyager Therapeutics
- 2026-06-29 12:01 EST — [Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026](https://biopharmsignal.com/news/VYGR/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-to-be-feature-7e183bb9) — Source: Voyager Therapeutics
- 2026-06-11 20:01 EST — [Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference](https://biopharmsignal.com/news/VYGR/voyager-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-hybrid-confer-3d59c3bb) — Source: Voyager Therapeutics
- 2026-06-01 12:00 EST — [Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease](https://biopharmsignal.com/news/VYGR/voyager-receives-fda-ind-clearance-for-vy1706-first-gene-therapy-approach-to-red-9cffdbcc) — Source: Voyager Therapeutics
- 2026-05-13 10:01 EST — [Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026](https://biopharmsignal.com/news/VYGR/voyager-asgct-late-breaker-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-i-daac488a) — Source: Voyager Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)